IN SILICO STUDY: SECONDARY METABOLITES FROM RED GINGER RHIZOME (Zingiber Officinale Var. Rubrum) AS POTENTIAL INHIBITORS OF3CLpro AND PLpro OF SARS-CoV-2
Main Article Content
Abstract
The COVID-19 outbreak prompted the development of novel drugs to treat the disease. Targeting of virus proteins has attracted great interest in the discovery of COVID-19 drugs. 3CLpro and PLpro are promising targets because of their important role in viral replication. Hence, various efforts have been made to find specific therapeutics for COVID-19, including those derived from plants as anti-Covid-19. Red ginger rhizome (Zingiber officinale var. rubrum) contains secondary metabolites that are known for their health benefits. This in silico study aimed to determine the potency of red ginger rhizome as PLpro and 3CLpro of SARS-CoV-2 inhibitor which may be applied to treat COVID-19. This research was conducted using molecular docking and molecular dynamics simulations. The molecular docking simulation of red ginger compounds in complex with SARS-CoV-2 PLpro showed that 27 compounds have a binding free energy (?G) lower than that of the reference ligand. On the other hand, none of the complexes between red ginger compounds and 3CLpro had a lower binding free energy than the reference ligand. Visualization of interaction features at the PLpro of SARS-CoV-2’s active site shows that secondary metabolites dominantly interact with hydrogen bonds. The ar-curcumene and PLpro complex of SARS-CoV-2 appears very stable and has the lowest flexibility compared to HBA as a native ligand and molnupiravir as a reference ligand based on RMSD and RMSF plot analysis using molecular dynamic simulation...
Article Details
Copyright Notice
 The author whose manuscript was published agreed to the following provisions:
- The publication right of all journal material published / released on the E-Journal website of the Medical Science Journal: The Pharmaceutical Scientific Journal is held by the editorial board with the author's knowledge (the moral rights remain the manuscript's author).
- Formal legal provisions for access to digital articles in electronic journals are subject to Creative Commons Attribution-ShareAlike (CC BY-SA) license terms, which means Medical Science Journal: Pharmaceutical Scientific Journal has the right to store, transfer media / format, manage in the form of database (database), maintain, and publish articles without asking permission from the author as long as they include the author's name as the copyright owner.
- Manuscripts that are published / released in print and electronically are open access for educational, research and library purposes. In addition to these objectives, the editorial board is not responsible for violations of copyright law.
Â
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.